SpringWorks Therapeutics’ lead candidate, Nirogacestat, for treating Desmoid tumors, is coming up for an FDA decision - PDUFA date - on 27 November.I believe that an FDA approval for Nirogacestat in ...
Source LinkSpringWorks Therapeutics’ lead candidate, Nirogacestat, for treating Desmoid tumors, is coming up for an FDA decision - PDUFA date - on 27 November.I believe that an FDA approval for Nirogacestat in ...
Source Link
Comments